Preclinical models for neuroblastoma: establishing a baseline for treatment
about
The zebrafish as a model for studying neuroblastomaTh-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model.miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAsNeuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.Expression of MYCN in Multipotent Sympathoadrenal Progenitors Induces Proliferation and Neural Differentiation, but Is Not Sufficient for Tumorigenesis.Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaMolecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.Detection of Phenotypic Alterations Using High-Content Analysis of Whole-Slide ImagesTargeting ALK in neuroblastoma--preclinical and clinical advancements.Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastomaEndoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF)Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.Immunocombination therapy for high-risk neuroblastoma.Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.Neuroblastoma models for insights into tumorigenesis and new therapies.Development and characterization of a human orthotopic neuroblastoma xenograft.Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways.A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma.Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts.Doxorubicin-provoked increase of mitotic activity and concomitant drain of G0-pool in therapy-resistant BE(2)-C neuroblastoma.MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.
P2860
Q28070309-662B2A9B-F2D6-434D-85D6-4AE2D853E745Q30541198-5A774FF7-E107-469B-A21F-354747A66256Q34051924-BD8C4CA5-4ECB-4B7B-AAAA-49D3DD883274Q34099211-0F3F2517-B75C-421D-A7B3-9C1EEE4C6293Q34438553-DB0D1075-78B7-4E1D-B6EE-7DB3C0A03231Q34531771-1F6B138F-914F-440D-9C88-62807143A53EQ35283020-0458A510-2824-47E2-943D-FE4F855247E7Q35546878-C9899653-986D-493B-BE52-8DE2B7B39446Q35723535-76390C66-3FAF-48A1-AF57-E32CE8258F53Q36108956-E212B327-D585-4B9E-908C-30CDA7C61780Q36281460-D29F8579-54AF-4E40-B94C-68EAB3134322Q36673633-CEDB17FB-B8B2-4818-811E-72B734DB259EQ36852426-283410C1-2B6C-4FF1-B2A6-2D1B6D4B7D55Q36933081-45BF31F9-B194-46DA-AA52-3C6C32B7F4A0Q37078946-86382DFB-3078-4CC9-886B-B302EF6B4A67Q37563444-DAC3E990-4C84-4A71-ABB0-F00858431C58Q37940719-F23EC179-72CB-4F9E-B945-9BD02EA93B98Q37991024-1E4EEA60-42D0-41A0-BE45-6BEEFA451B27Q38045441-DD831F1D-275D-4AE5-B94D-467EA8C091E9Q38262762-1CF7DD0E-F0F5-46A8-A9BA-3DBA1697D6F4Q38888609-49A2AC53-10DB-4017-A49D-CDB6CAC6B925Q38929374-247A03A2-A6FA-48B6-835D-359930A08848Q39095788-FEDB636D-B96B-4756-BF95-110CA526CAF9Q39113077-D1CD07D8-8649-4A6A-91D2-F8B814CACB1DQ40553571-2DBC555E-2056-4A0E-9C16-0CB7930FA2DDQ44997573-F7FEE0B6-5FAB-45C7-9AF9-D3B28ABE0752Q48226440-8FDB8097-C442-48F0-B72D-70D8FF0C2CECQ49647074-135F6DE7-5723-4763-8C50-BE514D4367D3
P2860
Preclinical models for neuroblastoma: establishing a baseline for treatment
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Preclinical models for neuroblastoma: establishing a baseline for treatment
@ast
Preclinical models for neuroblastoma: establishing a baseline for treatment
@en
type
label
Preclinical models for neuroblastoma: establishing a baseline for treatment
@ast
Preclinical models for neuroblastoma: establishing a baseline for treatment
@en
prefLabel
Preclinical models for neuroblastoma: establishing a baseline for treatment
@ast
Preclinical models for neuroblastoma: establishing a baseline for treatment
@en
P2093
P2860
P1433
P1476
Preclinical models for neuroblastoma: establishing a baseline for treatment
@en
P2093
Christopher Calabrese
Claudia M Hillenbrand
Cori L Bradley
David Finkelstein
Jan Sedlacik
Jennifer J Stanke
Jerold E Rehg
Jiakun Zhang
Jill M Lahti
Madoka Inoue
P2860
P304
P356
10.1371/JOURNAL.PONE.0019133
P407
P577
2011-04-29T00:00:00Z